Phase II study of regorafenib with dose adjustment and pharmacokinetic analysis in advanced colorectal cancer

ABSTRACT: Interventions: Start with regorafenib 120mg/day, and escalate the dosage to 160mg/day if compatible with the criteria at day 15 Primary outcome(s): Desease control rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2638141 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR